From Surf Wiki (app.surf) — the open knowledge base

Glaucoma medication

Eye condition medication

Summary

Eye condition medication

Field	Value
name	Glaucoma medication
image	Pfizer xalaTAN latanoprost eye drops.jpg
caption	Latanoprost
specialty	Ophthalmology

Glaucoma medication is divided into groups based on chemical structure and pharmacologic action. The goal of currently available glaucoma therapy is to preserve visual function by lowering intraocular pressure (IOP) in patients that have an increased intraocular pressure.

Medical uses

Agents in common clinical use include:

Prostaglandin analogs
Parasympathomimetic (miotic) agents, including cholinergic and anticholinesterase agents
Carbonic anhydrase inhibitors (oral and topical)
Adrenergic antagonists (nonselective and selective Beta1-antagonists)
Alpha 2 agonists
Hyperosmotic agents
Nitric oxide donators
Rho kinase inhibitors

When comparing people with primary open-angle glaucoma and ocular hypertension, medical intraocular pressure lowering treatment slowed down the progression of visual field loss.

Comparison table

Name	Other names	Mechanism of action	Dosage	IOP decrease	Side effects
Prostaglandin analogs
Latanoprost	Xalatan	Increased USO (uveoscleral outflow )	Once daily	25-32%	pigmentation of eyelashes, eyelid skin pigmentation, hyperemia (red eye), flu-like symptoms (joint/muscle pain and headache)
Bimatoprost	Lumigan	Increased USO (uveoscleral outflow )	Once daily		blurred vision, eyelid redness, eye discomfort, permanently darken iris, darken/thicken eyelashes
Travoprost	Travatan	Increased USO (uveoscleral outflow )	Once daily		blurred vision, eyelid redness, eye discomfort, permanently darken iris, darken/thicken eyelashes
Beta blockers
Timolol	Timoptic	Decrease aqueous production	Every 12 hours	20-30%	bronchospasm, bradycardia, depression, impotence
Betaxolol	Betoptic	Decrease aqueous production	Every 12 hours	15-20%	Fewer pulmonary complications due to selective Beta blockage
Adrenergic agents
Brimonidine	Alphagan	Decrease aqueous production, increase USO	every 8–12 hours	20-30%	blurring, foreign body sensation, eyelid edema, dryness, headache, fatigue, hypotension, depression, insomnia
Miotics
Pilocarpine	Isoptocarpine, Pilocar	Increase trabecular outflow	Every 6–12 hours	15-25%	posterior synechia, keratitis, miosis, brow ache, cataract, myopia, retinal tear, dermatitis, increased salivation
Carbonic anhydrase inhibitors
Dorzolamide	Trusopt	Decrease aqueous production	Every 8–12 hours	15-20%	eye irritation, bitter taste
Brinzolamide	Azopt	Decrease aqueous production	Every 8–12 hours	15-20%	eye irritation, bitter taste
Acetazolamide	Diamox	Decrease aqueous production	Every 6–12 hours	15-20%	malaise, depression, weight loss, kidney stones

Combinations

Pilocarpine/timolol Fotil is a combination drug consisting of:

Pilocarpine, a parasympathomimetic
Timolol, a beta-adrenergic receptor antagonist

References

"Nitric Oxide-Donating Drugs for IOP Lowering".
(2007-10-17). "Medical interventions for primary open angle glaucoma and ocular hypertension". The Cochrane Database of Systematic Reviews.
[[FASS (drug formulary)]]: [http://www.fass.se/LIF/product?userType=2&nplId=19920918000016 Fotil]. Retrieved 2015-02-17
Basic and clinical science course. (2011–2012). "Glaucoma". American Academy of Ophthalmology.
(2009). "Ophthalmology". Mosby Elsevier.

Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

glaucoma

Want to explore this topic further?

Ask Mako anything about Glaucoma medication — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report